STK4 and liver cancer: In in vitro experiments, SS-b2 has also exhibited dose dependency; the increase in STK4 protein expression in HepG2 liver cancer cells rose from 23.08% to 84.62%, while the reduction in IRAK1 protein expression increased from 22.73% to 40.91% and the reduction in phosphorylated NF-κB p65 protein expression increased from 12.00% to 52.00%.